Intra-Cellular Therapies, Inc. - COM (ITCI)

Historical Portfolio Holders from Q1 2014 to Q1 2024

All holders as of March 31, 2024
Q1 2024
Type / Class
Equity / COM
Shares, excl. options Q1 2024
85.8 M
Holdings value Q1 2024
$5.94 B
Value change Q1 2024
-$119 M
Grand Portfolio weight change Q1 2024
0%
Number of holders
325
Number of buys Q1 2024
163
Number of sells Q1 2024
-158
Average buys Q1 2024 %
+0.003%
Average sells Q1 2024 %
-0.003%
CUSIP
46116X101
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q1 85.8 M $5.94 B -$119 M $69.20 325
2023 Q4 87.8 M $6.29 B +$159 M $71.62 325
2023 Q3 85.7 M $4.47 B +$121 M $52.09 285
2023 Q2 82.8 M $5.25 B +$2.78 M $63.32 280
2023 Q1 83.4 M $4.52 B +$29 M $54.15 268
2022 Q4 83 M $4.39 B +$179 K $52.92 275
2022 Q3 82 M $3.81 B +$73.4 M $46.53 252
2022 Q2 79.7 M $4.55 B +$38.4 M $57.08 247
2022 Q1 79.5 M $4.86 B +$736 M $61.19 225
2021 Q4 67.9 M $3.55 B +$16.6 M $52.34 195
2021 Q3 68.2 M $2.54 B +$46.2 M $37.28 170
2021 Q2 67 M $2.73 B -$32.5 M $40.82 179
2021 Q1 67.9 M $2.3 B +$35.4 M $33.93 159
2020 Q4 67 M $2.13 B +$100 M $31.80 171
2020 Q3 63.7 M $1.63 B +$384 M $25.66 168
2020 Q2 48.7 M $1.25 B +$59.1 M $25.67 147
2020 Q1 46.5 M $715 M +$139 M $15.37 130
2019 Q4 38 M $1.3 B -$41.7 M $34.31 133
2019 Q3 39 M $291 M -$5.07 M $7.47 127
2019 Q2 38.3 M $497 M +$39.4 M $12.98 131
2019 Q1 38.2 M $465 M +$8.14 M $12.18 128
2018 Q4 37.9 M $432 M -$15.5 M $11.39 128
2018 Q3 38.1 M $826 M -$21.7 M $21.70 131
2018 Q2 38.6 M $681 M +$3.3 M $17.67 123
2018 Q1 39.4 M $829 M +$31.4 M $21.05 128
2017 Q4 37.6 M $543 M -$37.9 M $14.48 130
2017 Q3 40.5 M $636 M +$153 M $15.78 136
2017 Q2 30.9 M $384 M +$13.2 M $12.42 98
2017 Q1 28.9 M $469 M +$47.1 M $16.25 110
2016 Q4 29.7 M $448 M +$33.4 M $15.09 125
2016 Q3 27.9 M $424 M -$109 M $15.24 128
2016 Q2 30.1 M $1.17 B +$49 M $38.82 139
2016 Q1 29.1 M $808 M +$7.28 M $27.80 124
2015 Q4 28.5 M $1.53 B +$51.7 M $53.79 131
2015 Q3 27.6 M $1.1 B +$382 M $40.04 129
2015 Q2 17.8 M $570 M +$33.7 M $31.95 91
2015 Q1 17 M $405 M +$112 M $23.88 74
2014 Q4 12.2 M $215 M +$2.4 M $17.65 46
2014 Q3 12.1 M $166 M -$574 K $13.71 47
2014 Q2 12.1 M $204 M +$18 M $16.86 55
2014 Q1 11 M $201 M +$200 M $18.18 35